Psychometric validation of the functional assessment of cancer therapy—brain (FACT-Br) for assessing quality of life in patients with brain metastases

Thavarajah, Nemica; Bedard, Gillian; Zhang, Liying; Cella, David; Beaumont, Jennifer L.; Tsao, May; Barnes, Elizabeth; Danjoux, Cyril; Sahgal, Arjun; Soliman, Hany; Chow, Edward

doi:10.1007/s00520-013-2060-8

Cited by 43 publications

(33 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients can rate each item ranging from 0 "not at all" to 4 "very much" and the higher grades patients get, the higher HRQoL patients have [18]. Now, this questionnaire has been proved strong validity and reliability in testing psychosocial condition among both primary and secondary brain cancer patients [30,31].…”

Section: Questionnairementioning

confidence: 99%

Translation and Linguistic Validation of the Simplified Chinese Brain Cancer Patient-Reported Outcomes Evaluation System

Zhan

Yao

Xiao

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundThe Functional Assessment of Cancer Therapy Scale Brain Cancer-Specific Module (FACT-Br) was developed by a standard measurement theory and used to assess the symptoms, functions, and quality of life among brain cancer patients in English spoken countries. However, this instrument has not been translated into Chinese.ObjectiveThis study aimed to develop the Chinese version of the Functional Assessment of Cancer Therapy Scale Brain Cancer-Specific Module (C-FACT-Br).MethodsC-FACT-Br was translated following the standard Functional Assessment of Chronic Illness Therapy Translation (FACIT) methodology. Then, the cognitive briefing interviews were done to ensure the conceptual equivalence by probing 10 native Chinese-speaking brain cancer patients.ResultsThe translation was finished by bilingual teams with the help of the FACIT organization. All items in C-FACT-Br were understandable to patients, and they also gave some comments in adjusting items in scale.ConclusionsC-FACIT-Br items had the equivalence meaning, same structure, and harmonization with the English version. Brain cancer patients over 18 years old can understand the scale and express their symptoms, function, and quality of life by these measures.

show abstract

Section: Questionnairementioning

confidence: 99%

Translation and Linguistic Validation of the Simplified Chinese Brain Cancer Patient-Reported Outcomes Evaluation System

Zhan

Yao

Xiao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Temel et al 12 measured QoL, defined as their primary endpoint, using the validated Functional Assessment of Cancer Therapy (FACT). As our study is strongly influenced by the study of Temel e t al ,12 we also chose QoL as primary endpoint but using the specific module for brain tumour patients (FACT-Br) 33…”

Section: Introductionmentioning

confidence: 99%

“…Secondary endpoints will be changes in patients’ QoL measured by the TOI from baseline to 12 months (end of intervention), at 18 and 24 months of follow-up (to evaluate maintenance/sustainability of effect), full FACT-Br scale,33 patients’ PC needs, patients’ depression and anxiety, patients’ cognitive impairment, caregiver burden, each outcome measurement being validated and cost-effectiveness (costs per FACT-Br-unit) from the societal perspective including direct medical and direct non-medical costs 34. Moreover, data on overall survival and compliance will be collected.…”

Section: Introductionmentioning

confidence: 99%

Effect of early palliative care for patients with glioblastoma (EPCOG): a randomised phase III clinical trial protocol

Golla

Nettekoven

Bausewein³

et al. 2020

BMJ Open

View full text Add to dashboard Cite

IntroductionRandomised controlled trials (RCTs) have shown a positive effect of early integration of palliative care (EIPC) in various advanced cancer entities regarding patients’ quality of life (QoL), survival, mood, caregiver burden and reduction of aggressiveness of treatment near the end of life. However, RCTs investigating the positive effect of EIPC for patients suffering from glioblastoma multiforme (GBM) are lacking. After modelling work identifying the specific needs of GBM patients and their caregivers, the aim of this study is to investigate the impact of EIPC in this particular patient group.Methods and analysisThe recruitment period of this multicenter RCT started in May 2019. GBM patients (n=214) and their caregivers will be randomly assigned to either the intervention group (receiving proactive EIPC on a monthly basis) or the control group (receiving treatment according to international standards and additional, regular assessment of QoL (‘optimised’ standard care)).The primary outcome is QoL assessed by subscales of the Functional Assessment of Cancer Therapy for brain tumour (FACT-Br) from baseline to 6 months of treatment. Secondary outcomes are changes in QoL after 12 (end of intervention), 18 and 24 months (end of follow-up), the full FACT-Br scale, patients’ palliative care needs, depression/anxiety, cognitive impairment, caregiver burden, healthcare use, cost-effectiveness and overall survival.Ethics and disseminationThe study will be conducted in accordance with the Declaration of Helsinki and has been approved by the local ethics committees of the University Clinics of Cologne, Aachen, Bonn, Freiburg and Munich (LMU). Results of the trial will be submitted for publication in a peer-reviewed, open access journal and disseminated through presentations at conferences.Trial registration numberGerman Register for Clinical Studies (DRKS) (DRKS00016066); Pre-results.

show abstract

“…PRO measures are self-report questionnaires assessing patients' and/or caregivers' experiences with the disease and treatment-related symptoms, including quality of life, distress and the need for supportive care : Some of them are short questionnaires and can be used as screening tools (e.g. Anderson Symptom Inventory (MDASI and MDASI-BT, Armstrong et al, 2006;Thavarajah et al, 2014). In psychosocial screening, patients fill in self-reporting questionnaires that give further information about their well-being and supportive care needs as a basis for adequate treatment/intervention.…”

mentioning

confidence: 99%

“…the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 and EORTC QLQ-BN20 (Heimans & Taphoorn, 2002;Sprangers, Cull, Bjordal, Groenvold, & Aaronson, 1993;Taphoorn et al, 2010), the Functional Assessment of Cancer Therapy Questionnaire (FACT-G and FACT-Br) and the M.D. Anderson Symptom Inventory (MDASI and MDASI-BT, Armstrong et al, 2006;Thavarajah et al, 2014). However, Snyder et al (2009) were able to show in 2009 that a supportive care needs assessment should be added to distress screening and the measurement of hrQoL because the functional status or symptom burden may not always be sufficient to adequately conclude supportive care needs.…”

mentioning

confidence: 99%

Assessing psychological and supportive care needs in glioma patients - feasibility study on the use of the Supportive Care Needs Survey Short Form (SCNS-SF34-G) and the Supportive Care Needs Survey Screening Tool (SCNS-ST9) in clinical practice

et al. 2016

View full text Add to dashboard Cite

Neuro-oncological patients experience high symptom and psychosocial burden. The aim was to test feasibility and practicability of the Supportive Care Needs Survey Short Form (SCNS-SF34-G) and the SCNS-Screening Tool (SCNS-ST9) to assess supportive care needs of neuro-oncological patients in clinical routine. A total of 173 patients, most with a primary diagnosis of high-grade glioma (81%), were assessed first using SCNS-SF34-G in comparison to two well-established patient-reported outcome measures, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQC30 + QLQ-BN20) and Distress Thermometer (DT). In a follow-up assessment, SCNS-ST9 was used in a subgroup (n = 90). Questionnaires were completed either with personal guidance offered (group A) or by patients alone (group B). Feasibility was compared between instruments and groups for possible associations with patient and treatment-related factors. Missing values occurred in similar frequencies in all instruments. Errors in completion occurred in SCNS-SF34-G in 20% and in SCNS-ST9 in 16%; difficulties in completion were observed more often in SCNS-SF34-G and SCNS-ST9 (39%) compared to DT and EORTC (13%, p < .001). Distress was found to be associated with difficulties in completion of SCNS (OR 1.4, [95% CI 1.1-1.9], p = .013). SCNS-SF34 and SCNS-ST9 are suitable tools for glioma patients as long as personal guidance is offered.

show abstract

Psychometric validation of the functional assessment of cancer therapy—brain (FACT-Br) for assessing quality of life in patients with brain metastases

Abstract: The use of the combined FACT-G and FACT-Br Subscale to assess QoL specifically in patients with brain metastases has successfully undergone psychometric validation. Future clinical trials should use the FACT-G and FACT-Br Subscale to assess QoL in this patient population.

Cited by 43 publications

References 15 publications

Translation and Linguistic Validation of the Simplified Chinese Brain Cancer Patient-Reported Outcomes Evaluation System

Translation and Linguistic Validation of the Simplified Chinese Brain Cancer Patient-Reported Outcomes Evaluation System

Effect of early palliative care for patients with glioblastoma (EPCOG): a randomised phase III clinical trial protocol

Assessing psychological and supportive care needs in glioma patients - feasibility study on the use of the Supportive Care Needs Survey Short Form (SCNS-SF34-G) and the Supportive Care Needs Survey Screening Tool (SCNS-ST9) in clinical practice

Contact Info

Product

Resources

About